...
首页> 外文期刊>Journal of Clinical Oncology >Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
【24h】

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.

机译:伊曲康唑预防了接受血液系统恶性肿瘤治疗的中性粒细胞减少症患者的侵袭性真菌感染:一项对3597例患者进行荟萃分析的证据。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Efficacy of antifungal prophylaxis has not yet been convincingly proven in numerous trials of various antifungals. New evidence and the anti-Aspergillus efficacy of itraconazole prompted a new look at the data for the prevention of invasive fungal infections. PATIENTS AND METHODS: Randomized, controlled studies with itraconazole for antifungal prophylaxis in neutropenic patients with hematologic malignancies were identified from electronic databases and hand searching. RESULTS: Thirteen randomized trials included 3,597 patients who were assessable for invasive fungal infections. Itraconazole reduced the incidence of invasive fungal infection (mean relative risk reduction, 40% +/- 13%; P =.002), the incidence of invasive yeast infections (mean, 53% +/- 19%; P =.004) and the mortality from invasive fungal infections (mean, 35% +/- 17%; P =.04) significantly. The incidence of invasive Aspergillus infections was only reduced in trials using the itraconazole cyclodextrine solution (mean, 48% +/- 21%; P =.02) and not itraconazole capsules (mean, 75% +/- 73% increase; P =.3). The overall mortality was not changed. Adverse effects were rare, hypokalemia was noted in three studies, and a higher rate of drug discontinuation was found in trials that compared itraconazole cyclodextrine solution to a control without cyclodextrine. The effect of prophylaxis was clearly associated with a higher bioavailable dose of itraconazole. CONCLUSION: Antifungal prophylaxis with itraconazole effectively prevents proven invasive fungal infections and-shown for the first time for antifungal prophylaxis-reduces mortality from these infections and the rate of invasive Aspergillus infections in neutropenic patients with hematologic malignancies. Adequate doses of the oral cyclodextrine solution (at least 400 mg/d) or IV formulations (200 mg/d) of itraconazole are necessary for these effects.
机译:用途:各种抗真菌药的大量试验尚未令人信服地证明抗真菌药的预防作用。伊曲康唑的新证据和抗曲霉菌的功效促使人们对预防侵袭性真菌感染的数据有了新的认识。病人和方法:从电子数据库和人工搜索中确定了伊曲康唑对中性粒细胞减少症血液系统恶性肿瘤患者预防真菌的随机对照研究。结果:十三项随机试验包括3597例可评估侵袭性真菌感染的患者。伊曲康唑降低了侵袭性真菌感染的发生率(平均相对危险度降低,40%+/- 13%; P = .002),侵袭性酵母菌感染的发生率(平均53%+/- 19%; P = .004)以及侵袭性真菌感染的死亡率(平均35%+/- 17%; P = .04)。仅在使用伊曲康唑环糊精溶液的试验(平均48%+/- 21%; P = .02)中降低了侵袭性曲霉菌感染的发生率,而伊曲康唑胶囊的平均值(增加了75%+/- 73%; P = .3)。总死亡率没有改变。不良反应罕见,在三项研究中发现低血钾症,并且在将伊曲康唑环糊精溶液与不含环糊精的对照组进行比较的试验中发现停药率更高。预防作用显然与伊曲康唑的较高生物利用剂量有关。结论:伊曲康唑对真菌的预防有效地预防了已证实的侵袭性真菌感染,这是首次对真菌的预防,从而降低了这些感染的死亡率以及中性粒细胞减少性血液系统恶性肿瘤的侵袭性曲霉菌感染率。为达到这些效果,需要足够剂量的口服环糊精溶液(至少400 mg / d)或伊曲康唑IV制剂(200 mg / d)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号